Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (vrd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial